Dihydrotestosterone and inhibitors of steroid 5α-REDUCTASE
Authors:
prof. MUDr. RNDr. Luboslav Stárka, DrSc.
Authors‘ workplace:
Endokrinologický ústav
Published in:
Urol List 2007; 5(3): 11-16
Overview
In most mammalians, dihydrotestosterone (DHT) is a product of reduction of testosterone by steroid 5α-reductase (5α-RD). It plays a crucial role in the process of sexual differentiation of external genitalia in man. An example of its insufficient production due the 5α-dehydrogenase deficit is the Imperato- McGinley syndrome, in which mutations in type 2 isoenzyme of 5α-reductase cause male pseudohermaphroditism. The affected 46XY individuals have normal to elevated plasma testosterone levels with decreased DHT levels. They have ambiguous external genitalia at birth so that they are believed to be girls and are often raised as such. However, Wolffian differentiation occurs normally and they have epididymides, vas deferens and seminal vesicles. Virilization occurs at puberty frequently due to high testosterone levels, often associated with gender role change. The prostate in adulthood is small and rudimentary, and facial and body hair is absent or decreased. Balding has not been reported. Partial deficiency of 5α-reductase presents with micropenis, which can be corrected by dihydrotestosterone treatment in case of relative deficit of DHT. In normal individuals higher local concentrations of DHT play a key role in benign prostate hyperplasia or prostate carcinoma, but also in the development of male body hair. Administration of type 2 5α-reductase inhibitor, finasteride, has shown effective in the treatment of prostate hyperplasia and of androgenetic alopecia or hirsutism. Until now the physiological effects of DHT on chondrocytes during long-bone growth plate closure, spermatogenesis, especially on the maturation of spermatozoa in epididymis, on sexual brain differentiation and its action as a neuroactive steroid or the association of its higher levels with homosexuality has not been explained in detail and deserves further studies.
Key words:
dihydrotestosteronesteroid 5α-reductase, Imperato-McGinley syndrome, sexual differentiation, micropenis, alopecia, prostate
Sources
1. Dorfman RI, Cook JW, Hamilton JB. Conversion by the human of the testis hormone, testosterone, into the urinary androgen, androsterone. J Biol Chem 1939; 130: 285-295.
2. Borst SE, Lee JH, Conover CF. Inhibition of 5alpha-reductase blocks prostate effects of testosterone without blocking anabolic effects. Am J Physiol Endocrinol Metab 2005; 288(1): 222-227.
3. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243(8): 2012-2021.
4. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J Biol Chem 1968; 243(22): 5953-5960.
5. Russell DW, Wilson JD. Steroid 5 -reductase: two genes/two enzymes. Annu Rev Biochem 1994; 63: 25-61.
6. Sinisi AA, Pasquali D, Notaro A et al. Sexual differentiation. J Endocrinol Invest 2003; 26 (suppl 3): 23-28.
7. Tohda A, Matsumoto F, Shimada K, Okuyama A. Differentiation of external genitalia and 5 alpha-reductase. Nippon Rinsho 2004; 62(2): 275-280.
8. Mitamura K, Ogasawara C, Shiozawa A et al. Determination method for steroid 5alpha-reductase activity using liquid chromatography/atmospheric pressure chemical ionization-mass spectrometry. Anal Sci 2005; 21(10): 1241-1244.
9. Hampl R, Putz Z, Stárka L. Radioimunologické stanovení dihydrotestosteronu a jeho význam pro laboratorní diagnostiku. Biochem Clin Bohemoslov 1990; 19: 157-163.
10. Stárka L, Zamrazil V. Základy klinické endokrinologie. Praha: Maxdorf 2005: 323.
11. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186: 1213-1215.
12. Sinnecker GH, Hiort O, Dibbelt L et al. Phenotypic classification of male pseudoherma- phroditism due to steroid 5 -reductase 2 deficiency. Am J Med Genet 1996; 63: 223-230.
13. Cai LQ, Fratianni CM, Gautier T, Imperato-McGinley J. Dihydrotestosterone regulation of semen in male pseudohermaphrodites with 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1994; 79(2): 1409-1431.
14. Katz MD, Kligman I, Cai LQ et al. Paternity by intrauterine insemination with sperm from a man with 5alpha-reductase-2 deficiency. N Engl J Med 1997; 336(14): 994-997.
15. Imperato-McGinley J, Zhu YS. Androgens and male physiology the syndrome of 5alpha-reductase-2 deficiency. Mol Cell Endocrinol 2002; 198(1-2): 51-59.
16. Imperato-McGinley J, Gautier T, Pichardo M, Shackleton C. The diagnosis of 5 alpha-reductase deficiency in infancy. J Clin Endocrinol Metab 1986; 63(6): 1313-1318.
17. Katz MD, Cai LQ, Zhu YS et al. The biochemical and phenotypic characterization of females homozygous for 5 alpha-reductase-2 deficiency. J Clin Endocrinol Metab 1995; 80(11): 3160-3167.
18. Šulcová J, Stárka L, Jirásek JE. Transformation of testosterone into dihydrotestosterone by the primordia of human genitalia and by the fetal suprascapular skin. Steroids Lipids Res 1973; 4: 129-134.
19. Sasaki G, Ogata T, Ishii T et al. Micropenis and the 5alpha reductase 2 (SRD5A2) mutation and V89L polymorphism analysis in 81 Japanese patients. J Clin Endocrinol Metab 2003; 88(7): 3431-3436.
20. Negri-Cesi P, Colciago A, Celotti F, Motta M. Sexual differentiation of the brain: role of testosterone and its active metabolites. J Endocrinol Invest 2004; 27(suppl 6): 120-127.
21. Alias AG. A role for 5alpha-reductase activity in the development of male homosexuality? Ann N Y Acad Sci 2004; 1032: 237-244.
22. McLachlan RI, O'Donnell L, Meachem SJ et al. Identification of specific sites of hormonal regulation in spermatogenesis in rats, monkeys, and man. Recent Progr Hormone Res 2002; 57: 149-179.
23. Jarow JP, Zirkin BR. The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci 2005; 1061: 208-220.
24. Kolasa A, Marchlewicz M, Wenda-Rozewicka L, Wiszniewska B. Morphology of the testis and the epididymis in rats with dihydrotestosterone (DHT) deficiency. Rocz Akad Med Bialymst 2004; 49(suppl 1): 117-119.
25. Robaire B, Henderson NA. Actions of 5alpha-reductase inhibitors on the epididymis. Mol Cell Endocrinol 2006; 250(1-2): 190-195.
26. Henderson NA, Robaire B. Effects of PNU157706, a dual 5alpha-reductase inhibitor, on rat epididymal sperm maturation and fertility. Biol Reprod 2005; 72(2): 436-443.
27. Le H, Arnold JT, McFann KK, Blackman MR. DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab 2006; 290(5): E952-960.
28. Marks LS, Hess DL, Dorey FJ, Macairan ML. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology 2006; 68(2): 337-241.
29. Titus MA, Gregory CW, Ford OH 3rd et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11(12): 4365-4371.
30. Titus MA, Schell MJ, Lih FB et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11(13):4653-4657.
31. Giwercman YL, Abrahamsson PA, Giwercman A et al. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol 2005; 48(4): 679-685.
32. Friedman AE. The estradiol-dihydrotestosterone model of prostate cancer. Theor Biol Med Model 2005; 2(1): 10.
33. Torres JM, Ortega E. Steroid 5alpha-reductase isozymes in the adult female rat brain: central role of dihydrotestosterone. Mol Endocrinol 2006; 36(2): 239-245.
34. Bayne EK, Flanagan J, Einstein M et al. Immunohistochemical localization of types 1 and 2 5alpha-reductase in human scalp. Br J Dermatol 1999; 141(3): 481-491.
35. Hoffmann R, Happle R. Finasteride is the main inhibitor of 5alpha-reductase activity in microdissected dermal papillae of human hair follicles. Arch Dermatol Res 1999; 291(2-3): 100-103.
36. Laatikainen TJ, Apter DL, Paavonen JA, Wahlstrom TR. Steroids in ovarian and peripheral venous blood in polycystic ovarian disease. Clin Endocrinol 1980; 13(2): 125-134.
37. Chin D, Shackleton C, Prasad VK et al. Increased 5alpha-reductase and normal 11beta-hydroxysteroid dehydrogenase metabolism of C19 and C21 steroids in a young population with polycystic ovarian syndrome. J Pediatr Endocrinol Metab 2000; 13(3): 253-259.
38. Finn DA, Beadles-Bohling AS, Beckley EH. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006; 12(1): 53-76.
39. Sobel V, Schwartz B, Zhu YS et al. Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab 2006; 91(8): 3017-3023.
40. Raz P, Nasatzky E, Boyan BD et al. Sexual dimorphism of growth plate prehypertrophic and hypertrophic chondrocytes in response to testosterone requires metabolism to dihydrotestosterone (DHT) by steroid 5-alpha reductase type 1. J Cell Biochem 2005; 95(1): 108-119.
41. Seidlová-Wuttke D, Pitzel L, Thelen P, Wuttke W. Inhibition of 5alpha-reductase in the rat prostate by Cimicifuga racemosa. Maturitas 2006; 55(suppl 1): S75-82.
42. Wurzel R, Ray P, Major-Walker K et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2007; 10(2): 149-154.
43. Nickel JC. Comparison of clinical trials with finasteride and dutasteride. Rev Urol 2004; 6(suppl 9): 31-39.
44. Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol 2005; 7(4): 203-210.
45. Roberts JL, Fiedler V, Imperato-McGinley J et al. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol 1999; 41(4): 555-563.
46. Price VH, Menefee E, Sanchez M, Kaufman KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three- and 4-year results. J Am Acad Dermatol 2006; 55(1): 71-74.
47. Ryu HK, Kim KM, Yoo EA et al. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol 2006; 154(4): 730-734.
48. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8(1): 21-25.
49. McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs 1999; 57(1): 111-126.
50. Olsen EA, Hordinsky M, Whiting D et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006; 55(6): 1014-1023.
51. Iorizzo M, Vincenzi C, Voudouris S et al. Finasteride treatment of female pattern hair loss. Arch Dermatol 2006; 142(3): 298-302.
52. Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006; 6: 7.
53. Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002; 29(10): 665-669.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2007 Issue 3
Most read in this issue
- ERECTILE DYSFUNCTION FOLLOWING RADICAL PROSTATECTOMY
- Dihydrotestosterone and inhibitors of steroid 5α-REDUCTASE
- MALE CONTRACEPTION
- Is testosterone supplementation a potential risk for the prostate gland of an ageing male?